Topic 54

parkinsons pd synuclein parkinson dopaminergic disease neurons neuroscience substantia nigra neurodegenerative neurodegeneration dopamine aggregation lrrk2 syn motor alpha neuronal lewy synucleinopathies pathology dysfunction midbrain fibrils g2019s parkinsonian aggregates pathogenesis pathological neuron inclusions symptoms fibril induced disorders mice sporadic familial hallmark patients loss brain accumulation deficits cause mitochondrial kinase compacta striatal mechanisms bodies progressive model therapeutic synucleinopathy microglia dementia linked mouse onset a53t early neuroprotective misfolded degeneration protein overexpression altered asyn synaptic oxidative pars vitro risk mutations diseases progression vesicle nigral abnormal snca dysregulation pathway striatum implicated seeding common treatment pathogenic function aggregate levels atrophy injection autophagy toxicity pathophysiology induces formation

135 items. Top items listed below.

A new synuclein-transgenic mouse model for early Parkinson's reveals molecular features of preclinical disease 54 11 9 3

Complement and coagulation cascades are potentially involved in dopaminergic neurodegeneration in alpha-synuclein-based mouse models of Parkinson's disease 54 32


Transgenic mice expressing human alpha-synuclein in noradrenergic neurons develop locus coeruleus pathology and non-motor features of Parkinson's disease 54 11 10 3 2

Presynaptic accumulation of α-synuclein causes synaptopathy and progressive neurodegeneration 54 11 3

Rit2 reduces LRRK2 kinase activity and protects against alpha-synuclein neuropathology 54 11 3

Combined knockout of Lrrk2 and Rab29 does not result in behavioral abnormalities in vivo 54 30 10

Enhanced activity of glycolytic enzymes in Drosophila and human cell models of Parkinson's disease based on DJ-1 deficiency 54 10 3

Nicotinamide mononucleotide treatment increases NAD+ levels in an iPSC Model of Parkinsons Disease 54 11 10 3

Snca-GFP knock-in mice reflect patterns of endogenous expression and pathological seeding 54 11 3

Modeling Alpha-Synuclein Pathology in a Human Brain-Chip to Assess Blood-Brain Barrier Disruption in Parkinson's Disease 54 10 3

Alpha-synuclein supports interferon stimulated gene expression in neurons 54 27 10 3

Protection from α-synuclein-induced dopaminergic neurodegeneration by overexpression of the mitochondrial import receptor TOM20 in the rat midbrain 54 3

Dietary Amino Acids Impact LRRK2-induced Neurodegeneration in Parkinson's Disease Models 54 11 3

Highly enriched hiPSC-derived midbrain dopaminergic neurons robustly models Parkinson's disease. 54 11 3

Altered Thalamocortical Signaling in a Mouse Model of Parkinson's Disease 54 11 2

Antisense oligonucleotides targeting alpha-synuclein reduce pre-formed fibril-induced Lewy pathology and improve some domains of cognitive and motor performance 54 10

T cells limit accumulation of aggregate pathology following intrastriatal injection of α-synuclein fibrils 54 10

Pronounced α-synuclein pathology in a seeding-based mouse model is not sufficient to induce mitochondrial respiration deficits in the striatum and amygdala 54 10 2

Mitochondria-mitochondria interaction networks show altered topological patterns in Parkinson's disease 54

Multiple genetic pathways regulating lifespan extension are neuroprotective in a G2019S LRRK2 nematode model of Parkinson's disease 54 3

LRRK2 G2019S kinase activity triggers neurotoxic NSF aggregation 54 32 11 3

Glucocerebrosidase reduces the spread of protein aggregation in a Drosophila melanogaster model of neurodegeneration by regulating proteins trafficked by extracellular vesicles 54 3

High Content Screening and Proteomic Analysis Identify the Kinase Inhibitor BX795 as a Potent Neuroprotective Compound in a Patient-Derived Model of Parkinson's Disease 54 10 3

Alpha-MSH: Could this anti-inflammatory mediator be the culprit in Parkinson's Disease? 54 10 3

Neurodegeneration and neuroinflammation are linked, but independent of alpha-synuclein inclusions, in a seeding/spreading mouse model of Parkinson disease 54 32 3

Intra-mitochondrial proteostasis is directly coupled to alpha-synuclein and Amyloid β 1-42 pathology 54 32 3

CSPα reduces aggregates and rescues striatal dopamine release in αsynuclein transgenic mice 54 11 3

A human single-cell atlas of the Substantia nigra reveals novel cell-specific pathways associated with the genetic risk of Parkinson's disease and neuropsychiatric disorders. 54 32 9

The transcription factor BCL11A defines a distinctive subset of dopamine neurons in the developing and adult midbrain 54 11 3

The LRRK2 G2019S mutation alters astrocyte-to-neuron communication via extracellular vesicles and induces neuron atrophy in a human iPSC-derived model of Parkinson's disease 54 11 3

CRISPR/Cas9-mediated gene editing induces neurological recovery in an A53T-SNCA overexpression rat model of Parkinson's disease 54 33 10 3

A Multi-Scale Computational Model of Excitotoxic Loss of Dopaminergic Cells in Parkinson's Disease 54 11

α-Synuclein-112 impairs synaptic vesicle recycling consistent with its enhanced membrane binding properties 54 3

LRRK2 regulates AP2M1 phosphorylation cycles to mediate endocytosis and dopaminergic neurodegeneration 54 3

Rab27b regulates the release, autophagic clearance, and toxicity of alpha-synuclein 54 3

Parkinson's disease-related phosphorylation at Tyr39 rearranges α-synuclein amyloid fibril structure revealed by cryo-EM 54 51 8 3

Developmental exposure to the organochlorine pesticide dieldrin causes male-specific exacerbation of α-synuclein-preformed fibril-induced toxicity and motor deficits 54 15 10 2

Inhibiting the mitochondrial pyruvate carrier does not ameliorate synucleinopathy in the absence of inflammation or metabolic deficits 54 10 3

Interferon-γ signaling synergizes with LRRK2 in human neurons and microglia 54 3

Hsp27 reduces glycation-induced toxicity and aggregation of α-synuclein 54 3

Disulfide bridge formation prevents CaMKII/Calmodulin interaction in Parkinson's disease 54 3

Pathogenic LRRK2 R1441C mutation is associated with striatal alterations 54 11 10 3 2

Maintenance of mitochondrial integrity in midbrain dopaminergic neurons governed by a conserved developmental transcription factor 54 20 11 3

SNCAE46K transgenic Drosophila Model of Parkinsons Disease Confirmed the Causative Role of Oxidative Stress 54 3

α-Synuclein-induced Kv4 channelopathy in mouse vagal motoneurons causes non-motor parkinsonian symptoms 54 11 10

Protein synthesis is suppressed in sporadic and familial Parkinson's Disease by LRRK2 54 11 3

Effects of pharmacological modulators of α-synuclein and tau aggregation and internalization 54 32

Sequential screening nominates the Parkinson's disease associated kinase LRRK2 as a regulator of Clathrin-mediated endocytosis 54 9 3

Pathologic α-Synuclein Species Activate LRRK2 in Pro-Inflammatory Monocyte and Macrophage Responses 54 27 10 3

Metabolic defects cause hyperactive mitochondria and Parkinson disease-like traits 54 10 3

Perturbation of in vivo neural activity following α-Synuclein seeding in the olfactory bulb 54 11 2

Therapeutic Reversal of Chemically Induced Parkinson Disease by Converting Astrocytes into Nigral Neurons 54 11 10 3

Theoretical analysis predicts an optimal therapeutic strategy in distinct parkinsonian landscapes of the striatum 54 38 11

Effects of L-DOPA on gene expression in the frontal cortex of rats with unilateral lesion of midbrain dopaminergic neurons 54 9 2

Co-editing PINK1 and DJ-1 genes via AAV-delivered CRISPR/Cas9 system in adult monkey brains elicits classic Parkinsonian phenotypes 54 33

Targeted attenuation of elevated histone marks at SNCA alleviates α-synuclein in Parkinson's disease 54 31 3

Hsp70 chaperone blocks α-synuclein oligomer formation via a novel engagement mechanism 54 3

Criticality as a measure of developing proteinopathy in engineered human neural networks 54 2

JN403, an alpha-7-nicotine-acetylcholine-receptor agonist, reduces alpha-synuclein induced inflammatory parameters of in vitro microglia but fails to attenuate the reduction of TH positive nigral neurons in a focal alpha-synuclein overexpression mouse model of Parkinson's disease. 54 10 3

Functional and molecular early enteric biomarkers for Parkinson's disease in mice and men 54 10 3

PI31 expression prevents neuronal degeneration in a mouse Parkinson Disease model 54 11 10 3

Potent inhibitors of toxic alpha-synuclein oligomers identified via cellular time-resolved FRET biosensor. 54 8 3

Split-ends is modulating lipid droplet content in adult Drosophila glial cells and is protective against paraquat toxicity. 54 3

Dopamine Release Neuroenergetics in Mouse Striatal Slices 54 11 2

Discordant transcriptional signatures of mitochondrial genes in Parkinson's disease human myeloid cells 54 9 3

Oxidative switch drives mitophagy defects in dopaminergic parkin mutant patient neurons 95 54 3

Sexually dimorphic responses to MPTP found in microglia, inflammation and gut microbiota in a progressive monkey model of Parkinson's disease 164 54 10 2

Functional Analysis of Distinct Populations of Subthalamic Nucleus Neurons on Parkinson Disease and OCD-like Behaviors in Mice 54 11 10 3 2

Structures of α-synuclein filaments from multiple system atrophy 54 51

Whole genome CRISPR screens identify LRRK2-regulated endocytosis as a major mechanism for extracellular tau uptake by human neurons 54 32 3

α-Synuclein aggregation intermediates form fibril polymorphs with distinct prion-like properties 54 8

Transcriptomic analysis of dystonia-associated genes reveals functional convergence within specific cell types and shared neurobiology with psychiatric disorders 54 9

Characterization and validation of 16 α-synuclein conformation-specific antibodies using well-characterized preparations of α-synuclein monomers, fibrils and oligomers with distinct structures and morphology: How specific are the conformation-specific α-synuclein antibodies? 54

CyDAP-A fluorescent probe for cytosolic dopamine detection 54 11 2

IPSC-derived midbrain astrocytes from Parkinson's disease patients carrying pathogenic SNCA mutations exhibit alpha-synuclein aggregation, mitochondrial fragmentation and excess calcium release 6

Toward an early diagnostic marker of Parkinson's: measuring iron in dopaminergic neurons with MR relaxometry 54 11 2

Alpha-synuclein enhances lipid droplet accumulation in neurons in a Drosophila model of Parkinson's disease 54 3

Conserved nicotine-activated neuroprotective pathways involve mitochondrial stress 54 3

In situ architecture of neuronal alpha-Synuclein inclusions 54 8 3

Impaired hand dexterity function in a non-human primate model with chronic Parkinson's disease 54 15 2

Tau accumulates in Crohn's disease gut 54 10 3

A Computational Model of Levodopa-Induced Toxicity in Substantia Nigra Pars Compacta in Parkinson's Disease 54 10

Poly(ADP-ribose) induces α-synuclein aggregation in neuronal-like cells andinteracts with phosphorylated α-synuclein in post mortem PD samples 54 8 3

Observation of an α-synuclein liquid droplet state and its maturation into Lewy body-like assemblies 78 54 8 3

LRRK2 mutation alters behavioral, synaptic and non-synaptic adaptations to acute social stress 54 11 2

Perturbed DNA methylation by sustained overexpression of Gadd45b induces chromatin disorganization, DNA strand breaks and dopaminergic neuron death in mice 54 11 3

Network Analysis and Human Single Cell Brain Transcriptomics Reveal Novel Aspects of Alpha-Synuclein (SNCA) Biology 54 9

Pathogenic mutations in LRRK2 sequester Rab8a to damaged lysosomes and regulate transferrin-mediated iron uptake in microglia 54 3

Computational model of neurodegenerative damage in the olfactory bulb: role of bulb and damage geometry, damage site, and identification of a potential non-invasive marker of early Parkinson's disease onset 54 38 2

Formal model of Parkinson's disease neurons unveils possible causality links in the pathophysiology of the disease 54

Probing acetylated-α-synuclein monomer-aggregate complexes by NMR elucidates mechanism of fibril seeding 78 54 8 3

Reduced dopamine signaling impacts pyramidal neuron excitability in mouse motor cortex 11 2

Identification of bioactive metabolites in human iPSC-derived dopaminergic neurons with PARK2 mutation: altered mitochondrial and energy metabolism. 95 7 3

Differential dopaminergic modulation of spontaneous cortico-subthalamic activity in Parkinson's disease 54 42 2

Genetic reduction of PERK-eIF2α signaling in dopaminergic neurons drives cognitive and age-dependent motor dysfunction 54 11 3

Structure Specific Neuro-toxicity of α-Synuclein Oligomer 54 8

Integrated profiling of single cell epigenomic and transcriptomic landscape of Parkinson's disease mouse brain 54 9

Rab2 is a potent new target for enhancing autophagy in the treatment of Parkinson's disease 54 34 3

Attention and reinforcement learning in Parkinson's disease 22 2